Blog

Near-term applications include combinations with kinase inhibitors (KIs)that achieve enhanced concentration at target sites and synergistic delivery of multiple KIs to the same location

HOUSTON, TX / ACCESS Newswire / November 14, 2025 / BrYet US, Inc. – a biotechnology innovator focused on developing curative therapies for advanced cancers – announced today that it has expanded its patent portfolio with the issuance of U.S. Patent No. 12,390,420, titled “Compositions for Targeted Delivery of Therapeutic Agents and Methods for the Synthesis and Use Thereof.” The patent covers compositions and methods intended to guide therapies to target tissues and control their release using the company’s proprietary nanoporous silicon microparticles (NSMP) and multi-component architecture.

The newly-patented technology provides the foundation for a robust pipeline of therapies, with a near-term application in BrYet’s work pairing its proprietary platform with kinase inhibitors (KIs) – targeted medicines that help switch off overactive growth signals in some cancers.

Traditionally, the therapeutic efficacy of kinase inhibitors is often limited by poor drug delivery to tumor sites and the rapid development of drug resistance. The human body has a series of biological barriers that affect drug distribution and can prevent the desired accumulation of therapeutic agents at the cancer site while inducing adverse side effects. BrYet’s patented approach aims to improve the delivery of KIs by overcoming such biological barriers with a platform that comprises three elements: nanoporous silicon microparticles (NSMP), functional groups introduced to the surface of NSMP, and therapeutic drugs bound to the chemically modified NSMP through non-covalent interaction.

By packaging more than one KI together and releasing them at the same tumor site, BrYet aims to address treatment resistance with vertical and/or horizontal pathway inhibition. Rational combinatorial targeted therapies have been shown to enhance antitumor activity and overcome resistance to the therapy. Additionally, BrYet’s delivery platform is designed to minimize adverse side effects with lung-selective delivery.

“This patent expands the applications for our targeted approach to treating cancer,” said Dr. Mauro Ferrari, President and CEO of BrYet US, Inc. “It strengthens our ability to pair our delivery science with targeted medicines such as kinase inhibitors, bringing us one step closer to our ultimate goal of delivering functional cures.”

“By coordinating how and where each agent is released, we aim to improve the odds against therapeutic resistance and help patients in the greatest need,” said Dr. Masakatsu Eguchi, Senior Scientist of BrYet US, Inc. and the patent’s inventor.

BrYet plans to continue preclinical and clinical studies of its technology – including programs that combine targeted therapies such as KIs – and to explore partnerships to accelerate development toward the clinic.

Most recently, BrYet received Australian approval to begin its first-in-human clinical study of ML-016, the company’s lead therapeutic. ML-016 targets cancer-specific phenotypes in lung and liver cancers using the same vascular-targeting NSMP technology that will be used for the KI line.

About BrYet US, Inc.
BrYet is a privately held biotechnology company developing potentially first-in-class therapies for patients suffering from cancers for which there is no current curative treatment. BrYet’s lead asset, ML-016, is being developed for cancers of the lungs and liver, including advanced primary malignancies and metastatic spread from primary cancer that originates in other organs or tissue of the body. The company’s fundamental belief is that upon localization in the lungs and liver, these cancers acquire molecular transport phenotypes that are conserved regardless of site of origin and are largely independent of molecular mutations and their continued evolution. BrYet designs multi-component new chemical entities and formulations, which are directed against the fundamental aspects of these cancer-associated, organ-specific transport phenotypes. The company’s proprietary platforms include the mesoporous silicon components, and the mathematical formalism for designing the multi-component drugs, termed Transport Oncophysics. BrYet believes that similar approaches may provide advances against other forms of presently incurable cancers, as well as other pathologies of the lungs and liver. For more information about BrYet, please visit the company’s website: https://bryetpharma.com/

Safe-Harbor Statement

This press release contains forward-looking statements concerning BrYet and its business. These statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in this document, the words “expects,” “anticipates,” “estimates,” “intends,” “believes,” “plans,” “predicts,” “should,” “could,” “will,” and similar expressions are intended to identify forward-looking statements.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ from expectations. Factors that could contribute to these differences include the results of studies and clinical trials, regulatory approvals, challenges in clinical trials, the ability to retain employees, research and development expenses, reliance on third parties, intellectual property issues, competition, future funding needs, economic conditions, and other industry-specific risks. You should not place undue reliance on these statements, which are current as of the date of this press release. BrYet does not plan to update these statements unless legally required.

Media & Investor Contact
BrYet US, Inc.
2450 Holcombe Blvd., Suite 1520, Houston, TX 77021, USA
info@bryetpharma.com

SOURCE: Bryet US Inc.

View the original press release on ACCESS Newswire

RESEARCH TRIANGLE PARK, NC / ACCESS Newswire / November 13, 2025 / Cyberlux Corporation (OTC:CYBL), a leading defense technology innovator, today announced the next phase of the Company’s Defense Industry UAS Strategy, redefining how small Group 1 unmanned aircraft systems (UAS) are developed, produced, and deployed in modern conflict environments.

The next phase of strategy establishes Cyberlux as a driving force in attritable, high-impact UAS systems, designed to deliver mass, modularity, and mission adaptability at the lowest possible cost. By offering a FPV (First Person View) UAS as “ammunition, not aircraft,” Cyberlux aims to become the “Kalashnikov of drones” – delivering scalable, expendable systems to defense customers globally.

Revolutionizing Defense Through Attritable Economics

Cyberlux’s new models focus on delivering near front line production of UAV airframes using proven technology applied in new ways. These include unique methods of manufacture, 3D-printed systems, and traditional methods common to our expertise. The focus is on cost efficiency and scalability, with a variety of different offerings dependent on our partner’s requirements. NDAA-compliant for US Military sales as well as readably available commercial off-the-shelf (COTS) components for Foreign Military Sales (FMS). This multi-faceted approach enables defense customers and partner nations to choose how they wish to deploy drones rapidly, consistently, with production at or near the front lines.

Each Cyberlux-designed system can be licensed for local manufacture, providing partners with cost-effective production with vastly improved logistical considerations, while ensuring a scalable, forward-deployed supply chain for critical missions.

A Modular Family of FPV Systems

At the core of the strategy is a Family of Systems (FoS), each platform tailored to specific mission profiles, payloads, and operational environments:

• Spider (small) – Lightweight, low-cost rucksack-portable attritable strike-capable one way or single use FPV system delivering 1.5 lb. payloads.

• Huntsman (medium) – Tactical, low-cost FPV platform capable of attritable one-way strike and precision payload-delivery mission profiles of up to 4 lbs, bridging the gap between small expendables and fixed-wing systems.

• Tasmanian (large) – Heavy-lift, affordable, dual-use FPV capable of ISR and munitions delivery, with multiple gimbal options and 10 lbs payload capacity.

• Weaver (trainer) – Compact, affordable FPV training drone developed to establish Cyberlux as the premier provider of FPV operator training, addressing the DoD’s growing need for skilled UAS pilots, which can also be used for tactical reconnaissance by all troops.

This modular, scalable approach ensures each platform can be customized rapidly for mission-specific requirements – from electronic warfare (EW) and intelligence surveillance recognizance (ISR) payloads to kinetic payloads that builds on current partnerships such as the Optical Knowledge Systems, Inc. OMNISCIENCE™ autonomy suite artificial intelligence / machine learning (AI/ML) Integration Agreement and the Strategic Collaboration Agreement with Argus Industrial, LLC on kinetic payloads.

Training the Next Generation of UAS Operators

Recognizing that FPV piloting is a highly perishable skillset, the Cyberlux UAS strategy includes a dedicated training and simulation ecosystem. Through its Train-the-Trainer (T3) program, Cyberlux will deliver both hardware and curriculum solutions, empowering U.S. and allied forces to rapidly scale FPV proficiency across their ranks.

Positioned for Growth and Global Defense Leadership

“Cyberlux is leading the transformation of defense industry UAS from boutique systems into mass-production, mass-deployable, attritable munitions. Our objective is to make advanced UAS capability accessible and scalable for defense and allied customers fast to build, affordable to deploy, and lethal in effect,” said Mark Schmidt, CEO of Cyberlux Corporation. “By combining modular design, manufacturing licenses, and a comprehensive training ecosystem, we enable partners to field affordable, mission-effective systems while maintaining strict compliance with export controls and end-use safeguards.

Cyberlux is among only a handful of defense companies to have successfully delivered over 2,000 unmanned aerial systems under U.S. Department of Defense contracts, a milestone that underscores the company’s proven ability to move from concept to combat capability at scale. As a result, Cyberlux is positioned at the forefront of the next generation of battlefield autonomy, blending agility, affordability, and adaptability to meet the evolving demands of modern warfare.

SAFE HARBOR STATEMENT

This Press Release may contain forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s OTC/SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

For media inquiries, please contact:
Email: ir_cybl@Cyberlux.com | Phone: (984) 363-6894

SOURCE: Cyberlux Corporation

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / November 14, 2025 / A new kind of global contest is unfolding, one that is not powered by territory, ideology, or even traditional economic leverage. It is powered by certainty. Nations can invest in new mines, expand refineries, and build strategic reserves, yet none of it secures the future if no one can verify the origins of the materials driving modern industry. In this environment, truth becomes the rarest commodity of all. And into this vacuum steps SMX (NASDAQ:SMX), with a technology designed to act as a neutral referee for a world that no longer trusts its own supply chains.

For years, physical goods lived in a parallel universe to digital systems. The digital world advanced with verification, identity, and audit trails. The physical world advanced with paperwork, declarations, and good faith. That gap became a structural fault line. Critical materials-the elements that power defense systems, energy grids, renewable technologies, and industrial manufacturing-moved through opaque channels that left governments and corporations to rely on trust instead of evidence.

SMX is closing that gap by giving physical commodities a permanent, molecular identity. Its technology embeds microscopic chemical markers directly into materials, allowing them to carry an immutable record of their own origin and lifecycle. Plastics, metals, textiles, rubber, timber, and strategic minerals can now behave less like anonymous inputs and more like authenticated assets with built-in documentation.

A System Built for a Post-Trust Economy

This shift is happening because the old system simply cannot support the demands of the new world. Supply chains optimized for speed and outsourcing collapsed under geopolitical pressure. Trade disputes exposed the fragility of documentation. Sanctions and export bans revealed how easily materials could be mixed, relabeled, or substituted. Even the most advanced nations discovered they were dependent on unverifiable flows of critical goods.

SMX offers a counterweight to this instability. Its molecular markers survive heat, pressure, remelting, and full-scale industrial processing. Each material carries a verifiable signature that is readable in seconds, anywhere in the world, by any authorized scanner. Verification becomes the property of the material itself, not the paperwork surrounding it.

This changes the game. It allows investors to fund assets with confidence. It allows governments to enforce regulations with accuracy. It allows manufacturers to certify their supply chains without relying on declarations. It turns proof into an infrastructure layer, not an afterthought.

Why Global Powers Are Suddenly Paying Attention

Across Europe, Asia, and the United States, governments and financial institutions arepouring capital into rebuilding and reshoring supply lines. But investment alone cannot fill the void left by decades of fragmented verification. Mines can produce ore, refineries can process concentrates, and smelters can ship metals, but unless every step is authenticated, the system remains vulnerable.

SMX enters at this exact inflection point. Its technology is not nationalistic, ideological, or proprietary to any political bloc. It is neutral. It gives all participants-producers, regulators, distributors, auditors, and financiers-the same access to verifiable truth.

That neutrality is what gives SMX geopolitical gravity. It levels the playing field in a moment when trust between economic powers is at its lowest point in decades.

Where Verification Becomes Advantage

The real disruption lies in what happens after authentication becomes a built-in feature of materials. Supply chains stop behaving like chains and start behaving like transparent systems. Products stop needing to be proven. They prove themselves.

A shipment of rare earths can be verified before it crosses a border. A bale of recycled plastic can justify its premium instantly. A gold bar can confirm its lineage regardless of how many times it has been melted or recast. A textile can reveal its composition, durability, and sustainability claims without relying on marketing language.

Refiners gain precision. Banks gain confidence. Auditors gain clarity. Manufacturers gain integrity. And regulators gain enforcement mechanisms rooted in chemistry rather than documentation.

Textiles, metals, plastics, and critical minerals stop being debatable assets. They become self-evident.

The Stakes Are Now Structural, Not Just Economic

As the world races to stabilize supply chains and reduce reliance on fragile or adversarial sources, one weakness still threatens everything: the inability to verify origin. A single mislabeled shipment can contaminate an entire production line. A single fraudulent batch can undermine compliance reports or trigger geopolitical conflict.

SMX’s molecular system resolves this risk at its core. It eliminates ambiguity. It erases the gray zones. It replaces reliance with evidence and turns materials into transparent, traceable participants in the global economy.

This is not a theoretical promise. SMX is already operating across metals, textiles, plastics, rubber, and luxury goods, and is now being adapted to the rare earths and strategic minerals that will define the next industrial era.

A Neutral Referee in a Fractured World

The old global system was built on trust. The new global system requires verification. SMX’s technology-simple in function but profound in impact-offers exactly that. Not in service of one nation or ideology, but in service of stability itself.

In an era defined by geopolitical tensions, supply chain uncertainty, and escalating competition for strategic resources, neutrality is not a weakness. It is an anchor. SMX has built the infrastructure that allows global industry to operate without collapsing under its own doubt. It has created a way for nations to compete without destroying the integrity of the system they all rely on.

This is not a battle for dominance. It is a battle for credibility.
SMX built the technology that finally makes credibility measurable.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

This information contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Forward looking statements reflect current expectations, projections, and assumptions regarding future events that involve risks and uncertainties. These statements relate to SMX (NASDAQ:SMX), its molecular marking technologies, its commercial partnerships, and their potential application across critical minerals, metals, plastics, textiles, and global supply-chain verification systems.

Forward looking statements in this editorial include, but are not limited to, anticipated developments in the scalability, adoption, and commercial performance of SMX’s technology; potential integration of molecular-marking systems into national or industrial supply chains; expected benefits related to traceability, authentication, compliance, and lifecycle tracking of strategic materials; and assumptions regarding regulatory trends, geopolitical dynamics, sustainability mandates, and demand for verifiable supply-chain data across global industries.

These statements also involve assumptions about market acceptance of molecular authentication, investment activity within critical-materials infrastructure, technological performance under industrial conditions, and SMX’s ability to expand commercial deployments across multiple sectors and jurisdictions. Risks and uncertainties that may cause actual results to differ materially include changes in geopolitical conditions, supply-chain disruptions, regulatory shifts, partner implementation risks, competitive technologies, macroeconomic volatility, and the factors described in SMX’s filings with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

Readers are cautioned not to place undue reliance on forward looking statements. These statements speak only as of the date of publication. SMX undertakes no obligation to update or revise these statements to reflect future events, new information, or changes in circumstances, except as required by law.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / November 14, 2025 / For centuries, gold has existed outside the world of modern infrastructure. Digital identity systems have evolved. Financial instruments evolved. Global logistics has evolved. Yet gold, the very foundation of sovereign reserves and private wealth, remained an analog asset defined by trust, certificates, and manual verification.

That model is finally breaking.

SMX (NASDAQ:SMX), through its majority-owned subsidiary trueGold, has introduced the first technology that allows gold to function like a verified asset inside a modern financial system. The breakthrough comes not from a database or barcode, but from the metal itself. A molecular signature is embedded directly into gold at the earliest stage of extraction. That signature stays with the material through refining, casting, vaulting, trading, and recycling. It cannot be removed or forged. It becomes part of the infrastructure that governs the asset.

This shift is not theoretical. It is now operational.

trueGold’s technology has attracted a new strategic partner: Goldstrom, a global precious-metals group with operations spanning secure logistics, vaulting, trading, bullion banking, and wealth advisory. Their collaboration integrates trueGold’s molecular certification system into Goldstrom’s operational pipelines, transforming how gold is authenticated as it moves through institutional markets.

The combination forms a new infrastructure layer for the precious-metals economy. SMX provides the science. Goldstrom provides the scale. Together, they introduce a system in which verification is continuous and embedded, rather than external or discretionary.

The Backbone of a Verified Metals Network

trueGold’s platform consists of three elements: a molecular marker, a proprietary reader, and a digital registry that records each transfer. Once added, the chemical signature inside the gold becomes a permanent identity tag. It links physical matter to digital truth.

Independent testing by Intertek confirmed the marker’s safety and neutrality under the AnchorCert Pro 2 protocol, validating compliance across the United States, Canada, and the European Union. It does not alter the metal. It does not affect purity. It does not disrupt manufacturing or design. It simply turns gold into a self-identifying asset.

That capability now enters Goldstrom’s global footprint. Every movement through Goldstrom’s vaults, logistics centers, or banking channels can be tied to verified material identity. For the first time, a bullion ecosystem can operate with intrinsic proof instead of proxy documentation.

The value becomes clear when applied at scale. Regulatory frameworks shift from assumptions to evidence. ESG claims become measurable instead of declarative. Wealth managers gain the ability to prove provenance for institutional clients. Traders can validate recycled content, purity, and custody with unprecedented precision.

In a market where trust determines price, proof-based infrastructure is not a feature. It is an advantage.

The Regulatory Signal That Changes the Sector

The London Bullion Market Association has already recognized the significance of the technology by accrediting SMX’s molecular marker as a Gold Bar Security Feature. That endorsement is more than a technical milestone. It is an indicator that the world’s largest precious-metals authority accepts molecular proof as part of the authentication process.

With Goldstrom adopting the system, the infrastructure gains a runway for global deployment. A vault in Zurich, a refinery in Dubai, or a trading house in Singapore can operate on a shared identity layer that travels with the gold itself. Compliance becomes simpler. Fraud becomes harder. Market confidence strengthens.

And the timing aligns with global demand. IBM research shows that consumers are willing to pay substantial premiums for traceable products. PwC reports measurable margin expansion for verified sustainable sourcing. Those same behavioral patterns influence how bullion is valued, particularly among institutions that must justify ESG positions or provide transparent reporting.

trueGold and Goldstrom are not asking the market to imagine a future version of accountability. They are building the infrastructure today.

The Beginning of a Verified Financial Asset Class

This partnership represents more than a technology integration. It signals the emergence of a proof-ready asset class for precious metals.

Gold has always held value. Now it can verify that value. By embedding molecular identity directly into the metal and linking that identity to a secure digital registry, SMX and trueGold convert gold from an asset that relies on external trust into one that carries trust internally. Goldstrom extends that capability across global supply lines.

What began as a scientific breakthrough at SMX is becoming a new architecture for how markets authenticate one of the world’s most important commodities. The vaults, transfers, trades, audits, and recycling streams all become synchronized through chemistry and digital certainty.

In this new model, gold does not exist solely within the financial system. It becomes part of the system’s infrastructure. Proof is no longer something attached to an asset. It is something engineered into it.

And in this case, and for the first time in its history, gold can prove itself.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

This editorial contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Forward looking statements include expectations, projections, and assumptions about future events relating to SMX (NASDAQ:SMX), its majority-owned subsidiary trueGold, its partnership with Goldstrom, and the development and commercial expansion of molecular marking, digital registries, and supply chain verification technologies within the global precious-metals sector. These statements are not descriptions of historical facts. They are based on current beliefs, estimates, and assumptions that are inherently subject to risks, uncertainties, and factors that are difficult to predict.

Forward looking statements in this editorial include, but are not limited to, expectations regarding the integration of trueGold’s molecular-marking technology into Goldstrom’s operational framework; the potential widespread adoption of SMX-enabled verification across vaulting, logistics, bullion trading, banking, and wealth management; anticipated improvements in gold authentication processes; the potential for SMX systems to be recognized or mandated by regulatory bodies, including the London Bullion Market Association and other global metals authorities; and the anticipated value that verified provenance, traceability, and lifecycle tracking may bring to market participants, investors, and institutional clients.

These statements also encompass expectations about the potential scalability of SMX technology across refineries, recycling operations, manufacturing pipelines, and international metals markets; the ability of molecular identity markers to survive refining or remelting processes; the potential to enhance ESG reporting, sustainability claims, or compliance frameworks; and the possibility of establishing new economic models built on authenticated material identity. Forward looking statements further include assumptions about evolving consumer demand for transparent and traceable products; projected economic benefits from verified material flows; and the belief that proof-driven systems may influence commodity pricing, institutional adoption, and sector-wide operational standards.

These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks include, but are not limited to: changes in regulatory requirements affecting precious-metals trading and authentication; fluctuations in global commodity markets; geopolitical conditions; competitive technological developments; the pace at which institutional actors adopt new verification systems; technical limitations in deploying molecular markers at industrial scale; risks associated with integrating new technologies into established supply chains; general economic conditions; and other risks detailed in SMX’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

Readers are cautioned not to place undue reliance on forward looking statements. These statements speak only as of the date of publication. SMX undertakes no obligation to update or revise forward looking statements to reflect subsequent events, changes in circumstances, or new information, except as required by applicable law.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

LAS CRUCES, NEW MEXICO / ACCESS Newswire / November 13, 2025 / Electronic Caregiver, Inc. today announced outstanding clinical performance from a multi-state Medicare service test of Addison Care^®, the industry’s first 3D Virtual Caregiver designed to support chronically ill older adults at home with 24/7 intelligent care, guidance, and daily engagement.

The four-clinic test spanned primary care, vascular and cardiology practices, ranging from Arkansas to Alaska, and was structured as the final validation step to ensure that chronically ill older adults could:

1. Receive Addison Care^® in the mail

2. Plug it in at home

3. Turn it on without assistance

4. Successfully engage with the virtual caregiver interface

5. Use Addison Care^® daily for personalized health support

Results demonstrated not only high usability among elderly Medicare patients but also sustained engagement far exceeding historical national averages for Remote Patient Monitoring (RPM) and virtual chronic care programs.

Breakthrough Engagement Results

Across the first 82 patients, Addison Care^® achieved:

• 79% daily vitals compliance over a full measured month

• 71% daily vitals compliance in the most recent partial-month snapshot (13 days)

• 41,900+ patient-initiated interactive voice engagements over the study period

These levels of engagement are 2-4 times higher than traditional RPM systems, which nationally average 16-40% compliance after 60-90 days.

“This was not the industry’s 16-day engagement burst. Addison Care^® maintained daily vitals measurements and interactive use across the full 30-day analysis window and continued performing for months, sustaining 71-79% compliance. This consistency – and upward trend in engagement – represents a breakthrough in remote patient behavior and long-term digital adherence,” said Anthony Dohrmann, Founder and CEO of Electronic Caregiver.

Behavioral Impact: Engagement Improves Over Time

Unlike conventional RPM, where engagement declines sharply after the first 30-90 days, Addison Care^® demonstrated:

Consistent, steady, incremental improvement in patient engagement over time.

This confirms that the relational, avatar-led interface transforms the patient experience from device-based compliance into an emotionally supportive, daily health relationship.

A National Usability Success for Chronically Ill Older Adults

The test validated that:

• Older adults with chronic disease could successfully self-install the system

• The Addison Care^® interface was immediately understandable

• Early engagement was high and sustained

• Clinical workflows were correctly supported

The study served as the final accelerated validation before scaling Addison Care^® nationwide.

“This was not a lab test or a controlled usability trial – this was real Medicare patients across four clinical settings, from the Deep South to the most rural regions of Alaska,” said Dohrmann. “Addison Care^® proved it can be shipped directly to medically fragile older adults, turned on at home, and become an indispensable part of their daily health routine.”

Clinician Efficiency: 50 Hours Reduced to Minutes

With full integration into athenahealth^®, Addison Care^® automates the RPM and CCM billing workload:

• Billing tasks are generated automatically

• Clinicians simply review and click submit

• A typical 40-50 hour monthly billing workload drops to minutes

• Documentation is complete, accurate, and audit-ready

This eliminates one of the biggest barriers to long-term RPM adoption: administrative burden.

Operational Excellence & Nationwide Deployment Readiness

Electronic Caregiver’s national deployment infrastructure demonstrated exceptional stability and reliability throughout the four-clinic Medicare service test. Spanning multiple states and clinical specialties, Addison Care® proved it can be shipped, installed, activated, and relied upon by chronically ill older adults in real-world home environments.

Key Operational Performance Indicators

• Near-Perfect On-Time Delivery:
  Addison Care^® systems consistently arrived within required delivery windows across all pilot regions – including rural and remote locations – ensuring predictable onboarding and clinician confidence.

• 98-99% Activation Success (Post-Guide Revision):
  After the patient user guide was simplified, activation success stabilized at near-perfect levels, confirming that chronically ill Medicare patients can independently plug in and begin using Addison Care^® at home without technical assistance.

• 100% System Uptime for Patients:
  Over the four-month Medicare cohort window, system monitoring logs (220,375+ continuous runtime events) confirm Addison Care^® stayed online and available for patients essentially 100% of the time, supporting uninterrupted engagement and vitals monitoring.

• Multi-Site Consistency & Scalability:
  Engagement and activation results remained consistent across four organizations in four different states, validating that the platform performs the same regardless of geography, broadband variation, or clinic workflows.

• High Integrity of Patient Interaction Flows:
  The vitals management funnel shows steady user progression through the full vitals workflow (Launched → Path Selected → Completed), with:

  • 1,634 vitals workflow launches

  • 1,656 path selections

  • 1,286 completed vitals (≈79% completion rate) demonstrating both system stability and patient consistency.

• Robust Event Processing Capacity:
  With 30,283 total logged events and 41,939 voice commands, the system demonstrated reliable cloud communication, real-time telemetry, and high-frequency interaction without failures or outages.

The Final Step Before Nationwide Scale

“These four clinics proved that Addison Care^® is ready for national deployment,” Dohrmann added. “We now have the clinical validation, usability proof, operational capacity, and sustained patient engagement to scale tens of thousands of Addison Care^® units to patients who need personalized, 24/7 intelligent care support at home.”

Electronic Caregiver will now move into large-scale clinic deployment and expansion through Medicare, also expanding their programs for home care agencies, senior living providers, and other partners across the continuum of care.

About Electronic Caregiver

Electronic Caregiver, Inc. develops advanced virtual care technologies that support aging in place, chronic disease management, daily safety monitoring, and high-engagement patient interaction. Its flagship platform, Addison Care^®, integrates intelligent avatars, vitals monitoring, behavioral guidance, WiFi-based activity sensing, medication management, and emergency support to deliver a comprehensive, relational home-care experience. Addison Care^® integrates with leading EHR systems and powers scalable virtual care across clinics, home care agencies, and senior living markets.

Media Contact

media@ecg-hq.com
(575) 649-7808

SOURCE: Electronic Caregiver, Inc.

View the original press release on ACCESS Newswire

Local Grand Reopening November 15, 2025 12PM – 2PM to showcase Cutting-Edge Convenience and Personalized Service in a Next-Generational Format.

LEESBURG, GEORGIA / ACCESS Newswire / November 13, 2025 / Nibble Nation, LLC, a franchisee of Little Caesars, is proud to announce the grand reopening of its Leesburg store-with a fresh design and tech-forward ordering and pickup experience that reflects the brand’s latest prototype for speed and convenience.

New Look, New Experience

Building on Little Caesars’ reputation for Hot-N-Ready® value and convenience, our Leesburg location features the brand’s proprietary Pizza Portal®, the heated, self-service mobile-order pickup station that upends traditional counter waits. Guests who order ahead using the Little Caesars app will receive a QR code or PIN, arrive at our store and retrieve their pizza from the Pizza Portal in seconds.

Guests who want to walk in will be able to select from our Hot-N-Ready offerings and quickly check themselves out using our convenient kiosks-skipping any line altogether.

Why It Matters

In an era when convenience is king, we’re delivering on the core pillars of value, quality and convenience, while staying true to our local community roots.

What Guests Can Expect

• Order ahead via the Little Caesars app, pre-pay, and say goodbye to the counter entirely.

• Arrive at the store, grab your favorites, and pay with our friendly crew member.

• All the signature favorites: Hot-N-Ready pizzas, Crazy Bread®, Caesar Wings®, and new items like Crazy Puffs®-now with faster self-service pickup.

• Friendly local service and strong community focus

• Special Grand Reopening event: November 15, 2025 with music, giveaways, $5 pizza deals, and a live demo of the portal experience.

Join Us

November 15, 2025 12PM-2PM: We invite our Leesburg community and surrounding area to come see the new experience in action: faster, smarter, still great value. Whether you order via app, website or traditional counter, you’ll enjoy the same quality ingredients-fresh-made dough, vine-ripened tomato sauce, and never-frozen cheeses-with a pickup process designed for speed.

About Nibble Nation, LLC®

Nibble Nation, LLC has been franchising Little Caesars Pizza restaurants since 2006. Operated by Anthony King this location marks the next step in bringing the brand’s most advanced store format to the Leesburg / Albany metro region, while staying committed to our local community and team members.

About Little Caesars®

Headquartered in Detroit, Michigan, Little Caesars was founded in 1959 by Mike and Marian Ilitch. Today the brand operates in each of the 50 U.S. states and 28 countries and territories. Known for its Hot-N-Ready® value, Crazy Bread® and Pizza Portal® pickup innovation, Little Caesars remains one of the fastest-growing pizza chains in the world.

Contact Information

Anthony King
Anthony@nibblenation.com
(229) 256-4890

SOURCE: Nibble Nation LLC

View the original press release on ACCESS Newswire

IRVINE, CA / ACCESS Newswire / November 13, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of deep venous disease, today announced that it has received an unfavorable decision from the U.S. Food & Drug Administration (“FDA”) in response to its supervisory appeal of the not-approvable letter it received on August 19, 2025 in response to its Premarket Approval (PMA) application for VenoValve®, a surgical replacement venous valve for treating severe deep chronic venous insufficiency (CVI). The supervisory appeal upheld the review staff decision in the not-approvable letter that the VenoValve did not meet the standard of reasonable assurance of safety and effectiveness.

“Although the appeal decision was not the result we are looking for, it did provide valuable insight into the criteria that would be necessary for approval of enVVe, our next generation transcatheter based replacement venous valve,” said Robert Berman, enVVeno Medical’s Chief Executive Officer. “enVVe should have a different safety profile than an open surgical device and is ready for human testing. Assuming that we can reach alignment with the Agency on achieveble endpoints for enVVe, it makes sense to turn our attention and devote our resources to enVVe. We will continue to interact with the FDA on enVVe and will provide periodic updates on our progress.”

The Company reported $31.5 million in cash and investments at the end of the third quarter. With its quarterly cash burn of $4 to $5 million a quarter, the Company has sufficient cash to fund operations into 2027.

Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that there are approximately 2.5 million to 3.5 million patients with severe deep venous CV I in the U.S. including approximately 1.5 million patients that develop venous leg ulcers (C6 patients). The average patient seeking treatment of a venous ulcer spends as much as $30,000 a year on wound care, and the total direct medical costs from venous ulcer sufferers in the U.S. has been estimated to exceed $20 billion a year.

About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company is developing surgical and non-surgical replacement venous valves for the treatment of deep venous CVI.

Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
NVNO@jtcir.com
(908) 824-0775

MEDIA CONTACT:
Glenn Silver, FINN Partners
Glenn.Silver@finnpartners.com
(973) 818-8198

SOURCE: enVVeno Medical Corporation

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / November 14, 2025 / Most technologies disrupt a single sector. A rare few create an entirely new layer that industries plug into. SMX (NASDAQ:SMX) is doing the latter. Its molecular-marking architecture is not simply validating materials. It is creating the world’s first “proof mesh,” a global network where plastics, metals, fibers, and commercial goods report their own histories without the need for declarations, audits, or guesswork.

This mesh is forming through six strategic partnerships that turn verification into a structural function of global supply chains. Each partnership represents a different entry point. Each one expands the surface area where truth becomes automatic instead of asserted.

What makes the moment remarkable is not the number of partners, but the coherence of the system they now share. For the first time, regulators, manufacturers, investors, and recyclers can operate within a shared layer of authenticated material identity.

Singapore: The First Country to Wire Itself Into the Mesh

SMX’s work with A*STAR in Singapore represents the clearest example of national integration. The collaboration is building a plastics passport system where resin does not “claim” its past. It carries it. Every processing step becomes a certified event, allowing recycling incentives, waste policies, and industrial reporting to function with real-time certainty rather than assumptions.

Singapore is not running a circular-economy pilot. It is installing a backbone for verified material flow. Once complete, the country will operate the first nationwide proof mesh for plastics, setting a standard the world can study and adopt.

Austria: Machines That Sort and Certify Simultaneously

In Austria, SMX and REDWAVE are linking industrial automation directly into the proof mesh. Sorting machines traditionally separate materials by type. Now they can separate by identity. Molecular markers embedded in plastics allow REDWAVE systems to verify recyclate on the line.

Instead of waiting for lab tests or documentation, manufacturers receive immediate confirmation. A facility becomes a self-auditing environment. Quality becomes measurable in motion, not on paper.

When coupled with Tradepro’s distribution network in Miami, verified resin moves from European sorting lines to American supply chains with a clear, auditable trail that satisfies tightening U.S. recycled-content mandates.

Spain: Turning Industrial Pilots Into Proof Engines

CARTIF in Spain is positioning Europe’s circular economy for its next stage of implementation. Through its collaboration with SMX, the research center is embedding molecular identification into industrial testbeds that serve packaging, construction, renewable energy, and material-recovery programs.

These pilots function as conversion labs. They turn research into standards and standards into workflows that companies can deploy immediately. In an EU market where proof is becoming a prerequisite for access, CARTIF is ensuring that adoption becomes achievable rather than theoretical.

Metals With a Verified Memory

Gold and silver now have a voice inside the proof mesh. Through trueGold and the partnership with Goldstrom, SMX is embedding molecular identity into bullion at the earliest stage of handling. The result is a market where precious metals can authenticate themselves through every melt, recast, and transfer.

Banks gain stronger collateral. Refineries gain cleaner audits. Insurers gain lower risk. Investors gain something the metals industry has never consistently offered: authenticated provenance rooted in chemistry instead of certificates.

France: Textiles With Native Identity

In France, CETI is converting textile traceability from marketing language into operational fact. Its work with SMX equips fibers and fabrics with molecular IDs that persist through dyeing, weaving, recycling, and product assembly.

This turns garments into self-reporting assets. Brands can certify origin, recycled content, and lifecycle integrity. Lenders can attach sustainability-linked financing to datasets that cannot be manipulated. Retailers can differentiate verified textiles from unverifiable blends.

Identity moves from label to fiber.

The Proof “Mesh” Becomes an Economic Layer

Individually, each collaboration is meaningful. Together, they form a distributed verification layer that can be expanded across industries and borders. The mesh does not care what material is moving. It only cares whether the material can authenticate itself.

This is how value shifts; this is how compliance becomes predictable; and, this is how efficiency replaces bureaucracy.

SMX is not positioning itself as a tool supplier. It is emerging as the provider of the global proof layer that modern markets require. The mesh is growing, one connected partner at a time.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

This information contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Forward looking statements reflect current expectations, estimates, forecasts, and assumptions about future events involving SMX (NASDAQ:SMX), its molecular marker technologies, and its partnerships across multiple geographies and industry sectors. These statements are not historical facts. They involve risks, uncertainties, and factors that could cause actual results to differ materially from those expressed or implied.

Forward looking statements in this editorial include, but are not limited to, expectations regarding the continued development, adoption, and scalability of SMX’s molecular identification systems across plastics, metals, textiles, recycling facilities, and automated sorting environments; anticipated outcomes from collaborations with A*STAR in Singapore, REDWAVE in Austria, Tradepro in the United States, CARTIF in Spain, CETI in France, and Goldstrom in Singapore; projected improvements to supply chain transparency, regulatory compliance, and circular-economy performance; potential impacts on material quality, financing structures, insurance risk, and sustainability-linked reporting; and assumptions regarding the emergence of a global verification layer or ecosystem built around authenticated materials.

These statements also include assumptions about regulatory developments in the European Union, Asia-Pacific, and the United States; expected industry demand for verified recycled content; commercial viability of molecular-level tracking systems; adoption rates within the metals, textile, plastics, and recycling industries; macroeconomic conditions affecting supply chains; technological performance in industrial environments; and the ability of SMX to integrate its systems into diverse manufacturing workflows at scale.

Risks and uncertainties that could cause outcomes to differ include, but are not limited to, changes in environmental or trade regulations; disruptions in global supply chains; competitive technological developments; delays in partner implementation; limitations in scaling molecular markers across high-volume systems; economic volatility; shifts in consumer or manufacturer behavior; and other risks described in SMX’s filings with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

Readers are cautioned not to place undue reliance on forward looking statements. These statements speak only as of the date of publication. SMX undertakes no obligation to update or revise forward looking statements to reflect future events, new information, or changes in circumstances, except as required by applicable law.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

RESEARCH TRIANGLE PARK, NC / ACCESS Newswire / November 14, 2025 / Cyberlux Corporation, a leading developer of innovative unmanned aircraft systems (UAS), military communications platforms, and mission-critical defense technologies, today announced its operational achievements and strategic advancements for the third quarter ended September 30, 2025.

The quarter marked a consolidation period for the Company, highlighted by the post-contract deployment of its important completed U.S. Government contract, accelerated development across its NDAA-compliant UAS portfolio, a company-wide focus on manufacturing readiness, and the start of strategic partnerships that will elevate Cyberlux’s technological edge and global competitiveness.

Q3 2025 Operational Milestones

Deployment of the 2,000-Unit K8 UAS Delivery

Cyberlux successfully delivered all remaining K8 Unmanned Aircraft Systems to the U.S. Department of Defense on June 2, 2025, completing one of the largest Group 1 UAS delivery contracts ever executed by a U.S. manufacturer. During Q3 2025, Cyberlux continued to support the deployment of the K8 platform with various U.S. government customers. The program’s reinstatement and final delivery represent a major validation of Cyberlux’s ability to execute high-priority UAS manufacturing at scale.

Strong Backlog, Resumed Shipments, and Expanding Demand

For the quarter ended September 30, 2025, certain shipments were temporarily impacted by federal administrative delays and legal procedural matters, affecting approximately $9 million in Q3 shipments.

Shipments have now resumed, and the Company expects this timing shift to normalize fully during the next two quarters, Q4 2025 and Q1 2026.

Cyberlux enters the final quarter of 2025 with strong momentum:

● Approximately $20 million in current order backlog

● A robust additional pipeline of ~ $37.8 million across all business units

● Increasing demand from U.S. and allied defense partners for NDAA-compliant unmanned systems

This positions Cyberlux for significant 2026 revenue acceleration as production scales and global demand continues to rise.

Expansion of NDAA-Compliant UAS Portfolio

Cyberlux advanced its next-generation family of unmanned systems-each powered for high-performance operations in GPS- and RF-denied environments. Platforms moving into commercialization include:

● Weaver UAS (Trainer – Small 5″) – A rugged, soldier-carried tactical reconnaissance drone.

● Spider UAS (Small 7″) – Ultra-compact, rapid-deploy drone suitable for reconnaissance and kinetic missions.

● Huntsman (Medium – X4.10) – Mid-size Group 1 platform designed for ISR, payload delivery, and strike support.

● Tasmanian (Large – X4.18) – Heavy-lift Group 1 UAS with 10-lb payload capability and extended endurance.

The Company is preparing for global sales and high-volume production, with multiple allied nations already engaged in procurement discussions.

Strategic Partnerships Strengthening Cyberlux’s Competitive Advantage

Strategic Collaboration with Argus Industrial (July 2025)

Cyberlux entered into a Strategic Collaboration Agreement with Argus Industrial, LLC, a leader in munitions and precision UAS components. This partnership enhances Cyberlux’s mission capabilities with:

● Advanced fuse assemblies

● Integrated munition and effects payloads

● Expanded domestic manufacturing capacity

Palantir Warp Speed OS Integration for AI-Driven Manufacturing (Q2 2025)

Cyberlux announced its strategic initiative with Palantir Technologies in Q2 2025. This initiative continues in the development phase to deploy Palantir’s Warp Speed Operating System across Cyberlux’s entire manufacturing and supply chain infrastructure.

Warp Speed OS will enable:

● Real-time visibility across production, sourcing, and logistics

● AI-driven resource planning and supply chain orchestration

● Increased throughput for high-volume UAS manufacturing

● Greater agility to meet accelerating global demand

Innovation Partnership with George Mason University (Q2 2025)

Cyberlux and George Mason University (GMU) entered into a Memorandum of Understanding to collaborate across advanced research domains including during Q2 2025. This collaboration began moving forward in Q3 2025, with important progress expected during the first half of 2026:

● 5G and next-generation communications

● Cybersecurity

● Autonomous systems and unmanned aerial technologies

● Tactical communications innovation

Strengthening of Production and Global Readiness

Throughout Q3, Cyberlux continued scaling its production infrastructure to support higher-volume manufacturing. Key advancements include:

● NDAA-compliant component sourcing for all UAS platforms and future Blue List participation

● Production planning and process optimization for large-scale builds

● Supply chain investment to support U.S. and foreign military demand

● Renewed focus on the Datron Military Communications operations and ISO9000 manufacturing

These upgrades enhance Cyberlux’s ability to deliver reliable, mission-critical systems at rapid tempo.

Financial Position Update

During Q3 2025, Cyberlux continued to invest in Datron RF and HF capability, in next-generation UAS development with a focus on autonomy integration, and in the stabilization of the Company’s manufacturing capacity, aligning operational resources with the Company’s long-term growth strategy. These areas of focus support the Company’s vision of providing program-level high-margin, scalable production, as domestic and international demand increases across its three business units.

Temporary Authorized Share Increase – No Significant Dilution Planned

As part of our ongoing financing activities, the Company was required to temporarily increase its authorized shares to 9.0 billion to satisfy technical lender accounting criteria. This increase does not affect the number of shares outstanding and is not associated with any dilution to shareholders.

The Company’s actual outstanding shares will increase slightly from the current approximately 6.59 billion shares. Upon completion of the loan-related accounting procedures, management has a plan to reduce the outstanding shares back down to roughly 6.1 billion, consistent with our commitment to responsible share structure management and long-term shareholder value.

Looking Ahead

Cyberlux CEO Mark Schmidt commented:

“Cyberlux is entering an important new phase as we deliver on our global radio demand and next-generation unmanned systems capability, while expanding our strategic partnerships, and scaling our manufacturing capabilities. The advancements made this quarter set the stage for a return to the growth we experienced in prior quarters, both domestically and internationally, during 2026 and beyond.”

About Cyberlux Corporation

Cyberlux Corporation (OTCID:CYBL) develops and delivers innovative defense technologies including unmanned aircraft systems (UAS), tactical RF and HF communications, and advanced mission-support solutions for U.S. and allied government agencies worldwide.

SAFE HARBOR STATEMENT

This Press Release may contain forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s OTC/SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

For media inquiries, please contact:
Email: ir_cybl@Cyberlux.com | Phone: (984) 363-6894

SOURCE: Cyberlux Corporation

View the original press release on ACCESS Newswire

The veterans advocate, nationally known for his “Men’s Health’ cover and ‘Dancing with the Stars’ appearance, uses the sustained acoustic medicine device to help him stay fit and maintain his busy schedule.

TRUMBULL, CONNECTICUT / ACCESS Newswire / November 14, 2025 / U.S. Army veteran Noah Galloway’s journey has taken him from being gravely wounded in Iraq to the cover of Men’s Health magazine to a third-place finish on “Dancing with the Stars” and a role as a national veterans’ advocate. Galloway credits ZetrOZ System‘s sam® wearable ultrasound device for helping him manage his chronic pain and recover from years of overuse and training.

Galloway, the newest ambassador for sam®, was prescribed the device from his doctors at the Department of Veterans Affairs and has been pleased with the results.

“So many veterans and athletes deal with chronic pain and turn to medication because they don’t see another option. Tools like sam® give us control,” Galloway said. “It’s effective, safe, and helps the body heal naturally. That’s huge for anyone trying to stay active and live without being dependent on pills or surgery.”

Sustained acoustic medicine, provided by ZetrOZ Systems’ sam® device, is a continuous, multi-hour ultrasound therapy that penetrates soft tissue, reduces inflammation, improves circulation, and accelerates the natural healing process.

The sam® device has been proven effective in more than 20 Level 1-5 clinical studies and 40 peer-reviewed journal articles, and through over 3.7 million patient treatments. sam® is the only long-duration ultrasound device cleared by the U.S. Food & Drug Administration for home use.

“sam® is easy to use, portable, and allows me to target areas that need attention without relying on medication or long clinic visits,” Galloway said. “It keeps me in the game, which means I can stay consistent with my workouts and my speaking schedule.”

Galloway has been an active advocate for veterans since his return from Iraq. He was serving his second deployment with the 101st Airborne Division (Fort Campbell, Kentucky) when a roadside bomb explosion cost him his left arm and leg.

“Coming home was one of the hardest battles I’ve ever faced,” Galloway said. “Fitness became the tool that helped me rebuild, not just my body but my mind. The discipline, accountability, and resilience I learned in the military carried over into how I train and recover. It’s about adapting, not quitting. Every day I move my body is a reminder that I’m still here, and that’s something I’ll never take for granted.”

Now Galloway relies on sam® to help him recover more quickly from his workouts. “Recovery from a workout is just as important as the workout itself,” he said. “I deal with a lot of overuse on my right side, especially from training and the demands of prosthetics. sam® has been a big help.”

Galloway’s recovery has led to national prominence as a motivational speaker and advocate for veterans. “Becoming the first veteran and amputee on the cover of Men’s Health and being named their ‘Ultimate Guy’ was a huge honor because it represented more than a magazine cover. It was proof of what’s possible when you don’t give up. Competing on ‘Dancing with the Stars’ pushed me far outside my comfort zone and reminded me that vulnerability can be powerful.”

“But the most meaningful moments come when someone tells me that my story motivated them to get back up and fight through their own struggle. That’s what keeps me doing what I do.”

For more information about ZetrOZ Systems and the sam® wearable ultrasound device, visit www.zetroz.com or www.samrecover.com.

About ZetrOZ Systems

ZetrOZ Systems is the inventor of sustained acoustic medicine and a leader in healing innovations for sports medicine, developing FDA-cleared wearable bioelectronic devices to deliver sam® technology. Built on proprietary medical technology of 48 patents, ZetrOZ is the exclusive manufacturer of the sam® product line for treating acute and chronic musculoskeletal conditions.

SOURCE: ZetrOZ Systems

Related Images

View the original press release on ACCESS Newswire